Evidence map›Paper›PMID 36311763›Full record

ArticleFrontiers in immunology2022

Sorting nexin 17 increases low-density lipoprotein receptor-related protein 4 membrane expression: A novel mechanism of acetylcholine receptor aggregation in myasthenia gravis.

Xiaoxiao He, Shuxian Zhou, Ying Ji, Yingna Zhang, Jie Lv, Shangkun Quan, Jing Zhang, Xue Zhao, Weike Cui, Wenbo Li and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 1 country.

Xiaoxiao HeBGI College, Zhengzhou University, Zhengzhou, China.
Shuxian ZhouDepartment of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
Ying JiDepartment of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
Yingna ZhangDepartment of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
Jie LvDepartment of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
Shangkun QuanDepartment of Pathophysiology, School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, China.
Jing ZhangDepartment of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
Xue ZhaoDepartment of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
Weike CuiBGI College, Zhengzhou University, Zhengzhou, China.
Wenbo LiDepartment of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
Peipei LiuDepartment of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
Linyuan ZhangBGI College, Zhengzhou University, Zhengzhou, China.
Tong ShenDepartment of Encephalopathy, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.
Hua FangDepartment of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
Junhong YangDepartment of Encephalopathy, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.
Yunke ZhangDepartment of Encephalopathy, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.
Xinzheng CuiMyasthenia Gravis Comprehensive Diagnosis and Treatment Center, Henan Provincial People's Hospital, Zhengzhou, China.
Qingyong ZhangMyasthenia Gravis Comprehensive Diagnosis and Treatment Center, Henan Provincial People's Hospital, Zhengzhou, China.
Feng GaoDepartment of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
Zhengzhou University · CNFirst Affiliated Hospital of Henan University · CNHenan Provincial People's Hospital · CNNingxia Medical University · CNSecond Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myasthenia gravis (MG) is characterized by autoimmune damage to the postsynaptic membrane of the neuromuscular junction (NMJ) with impaired postsynaptic acetylcholine receptor (AChR) aggregation. Low-density lipoprotein receptor-related protein 4 (LRP4) plays an important role in AChR aggregation at endplate membranes

Indexed as

Myasthenia Gravis, Autoimmune, ExperimentalReceptors, CholinergicAcetylcholineAnimalsLDL-Receptor Related ProteinsLipoproteins, LDLMiceReceptor Protein-Tyrosine KinasesSorting NexinsAcetylcholineLDL-Receptor Related ProteinsLipoproteins, LDLReceptor Protein-Tyrosine KinasesReceptors, CholinergicSnx17 protein, mouseSorting Nexinsacetylcholine receptorendplate membraneslow-density lipoprotein receptor-related protein 4myasthenia gravissorting nexin 17

Identifiers

PMID36311763
PMCPMC9601310
OpenAlexW4304695151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.